HIV-1 viral protein-R (VPR) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo

Molecular Therapy

Volumn 12, Issue 5, 2005, Pages 910-921

  Muthumani, Karuppiah ^a   Choo, Andrew Y ^b   Hwang, Daniel S ^a   Dayes, Nathanael S ^a   Chattergoon, Michael ^a   Mayilvahanan, Shanmugam ^c   Thieu, Khanh P ^a   Buckley, Peter T ^a   Emmanuel, Joann ^a   Premkumar, Arumugam ^d   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytokine; Glucocorticoid receptor; HIV 1 Vpr; NF B; Sepsis; Staphylococcal endotoxin B; T cell activation

Indexed keywords

ENDOTOXIN; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SUPERANTIGEN; VPR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HOMEOSTASIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LYMPHOCYTE ACTIVATION; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN TARGETING; SEPSIS; SHOCK; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENDOTOXINS; FEMALE; GENE PRODUCTS, VPR; HIV-1; HOMEOSTASIS; LIVER; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; NF-KAPPA B; STAPHYLOCOCCUS; T-LYMPHOCYTES;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 27744440829     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.05.009     Document Type: Article

References (50)

1. A. Wheeler and G.R. Bernard Treating patients with severe sepsis N. Engl. J. Med. 340 1998 207-214
2. F. Zeni B. Freeman and C. Natanson Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment Crit. Care Med. 25 1997 1095-1100
3. Anonymous Increase in national hospital discharge survey rates for septicemia-United States 1979-1987 Morbid. Mortal. Weekly Rep. 39 1990 31-34
4. D. Angus W.T. Linde-Zwirble J. Lidicker G. Clermont J. Carcillo and M.R. Pinsky Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care Crit. Care Med. 29 2001 1303-1310
5. R. Balk Severe sepsis and septic shock: Definitions, epidemiology, and clinical manifestations Crit. Care Clin. 16 2000 179-192
6. R. Balk Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock Crit. Care Clin. 16 2000 337-352
7. S. Sriskandan and J. Cohen Gram-positive sepsis, mechanisms and differences from gram-negative sepsis Infect. Dis. Clin. North Am. 13 1999 397-412
8. E. Feil and B.G. Spratt Recombination and the population structures of bacterial pathogens Annu. Rev. Microbiol. 55 2001 561-590
9. J. McCormick J.M. Yarwood and P.M. Schlievert Toxic shock syndrome and bacterial superantigens: An update Annu. Rev. Microbiol. 55 2001 77-104
10. E.A. Cohen G. Dehni J.G. Sodroski and W.A. Haseltine Human immunodeficiency virus vpr product is a virion-associated regulatory protein J. Virol. 64 1990 3097-3099
11. W.A. Haseltine Molecular biology of the human immunodeficiency virus type 1 FASEB J. 5 1991 2349-2360
12. D.N. Levy L.S. Fernandes W.V. Williams and D.B. Weiner Induction of cell differentiation by human immunodeficiency virus 1 vpr Cell 72 1993 541-550
13. J. He S. Choe R. Walker P. Di Marzio D.O. Morgan and N.R. Landau Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle inhibiting p34 cdc2 activity J. Virol. 69 1995 6705-6711
14. M. Emerman HIV-1 Vpr and the cell cycle Curr. Biol. 6 1996 1096-1103
15. V. Ayyavoo et al. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B Nat. Med. 3 1997 1117-1123
16. R.A. Subbramanian et al. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages J. Exp. Med. 187 1998 1103-1111
17. S. Stewart B. Poon J.B. Jowett Y. Xie and I.Y. Chen Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells Proc. Natl. Acad. Sci. USA 96 1999 12039-12043
18. E. Jacotot et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore J. Exp. Med. 191 2000 33-46
19. K. Muthumani et al. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and PBMC's J. Biol. Chem. 277 2002 16639-16647
20. V. Ayyavoo et al. HIV-1 viral protein R compromises cellular immune function in vivo Int. Immunol. 14 2002 13-22
21. K. Muthumani et al. HIV-1 Vpr and anti-inflammatory activity DNA Cell Biol. 23 2004 239
22. M. Mirani I. Elenkov S. Volpi N. Hiroi G.P. Chrousos and T. Kino HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: Potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection J. Immunol. 169 2002 6361-6368
23. T. Kino A. Gragerov J.B. Kopp R.H. Stauber G.N. Pavlakis and G.P. Chrousos The HIV-1 virion-associated protein vpr is a coactivator of the glucocorticoid receptor J. Exp. Med. 4 1999 51-62
24. J.J. Kim Using viral genomics to develop viral gene products as a novel class of drugs to treat human ailments Biotechnol. Lett. 23 2001 1015-1020
25. V.N. Kewalramani C.S. Park P.A. Gallombardo and M. Emerman Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect Virology 218 1996 326-334
26. M.P. Sherman et al. HIV-1 Vpr displays natural protein-transducing properties: Implications for viral pathogenesis Virology 302 2002 95-105
27. K. Muthumani S. Kudchodkar E. Papasavvas L.J. Montaner D.B. Weiner et al. V. Ayyavoo HIV-1 Vpr regulates expression of beta chemokines in human primary lymphocytes and macrophages J. Leukocyte Biol. 68 2000 366-372
28. C. Du and S. Sriram Induction of interleukin-12/p40 by superantigens in macrophages is mediated by activation of nuclear factor-kappaB Cell. Immunol. 199 2000 50-57
29. M. Bozza et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis J. Exp. Med. 189 1999 341-346
30. + T cells Immunology 103 2001 270-280
31. + T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV Blood 102 2003 2156-2164
32. G. Arad R. Levy D. Hillman and R. Kaempfer Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation Nat. Med. 6 2000 414-421
33. J.M. Cavaillon H. Muller-Alouf and J.E. Alouf Cytokines in streptococcal infections: An opening lecture Adv. Exp. Med. Biol. 418 1997 869-879
34. J.W. Boles et al. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity Clin. Immunol. 108 2003 51-59
35. H. Iwadou et al. Differential cytokine response in host defence mechanisms triggered by gram-negative and gram-positive bacteria, and the roles of gabexate mesilate, a synthetic protease inhibitor J. Int. Med. Res. 30 2002 99-108
36. M. Karin and Y. Ben-Neriah Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity Annu. Rev. Immunol. 18 2000 621-623
37. N. Auphan J.A. DiDonato C. Rosette A. Helmberg and M. Karin Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis Science 270 1995 286-290
38. S. Ghosh et al. D. Baltimore Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B Nature 344 1990 678
39. L.P. Kane J. Lin and A. Weiss It's all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation Trends Immunol. 23 2002 413-420
40. A.S. Baldwin The NF-kappa B and I kappa B proteins: New discoveries and insights Annu. Rev. Immunol. 14 1996 649
41. P. Goettelfinger R. Roussin F. Lecerf S. Berrih-Aknin and M. Fattal-German T-cell deletion and unresponsiveness induced by intrathymic injection of staphylococcal enterotoxin B Transplant. Immunol. 8 2002 39-48
42. W. Stohl et al. In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: Dependence upon CD4(+) cells and human MHC class II Int. Immunol. 13 2001 1291-1300
43. K. Muthumani et al. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques J. Med. Primatol. 31 2002 179-185
44. Y.W. Choi A. Herman D. DiGiusto T. Wade P. Marrack and J. Kappler Residues of the variable region of the T-cell-receptor beta-chain that interact with S. aureus toxin superantigens Nature 346 1990 471-473
45. M.J. Irwin K.R. Hudson J.D. Fraser and N.R. Gascoigne Enterotoxin residues determining T-cell receptor V beta binding specificity Nature 359 1992 841-843
46. N.L. Letvin Progress in the development of an HIV-1 vaccine Science 280 1998 1875-1880
47. + T-cell depletion in HIV disease Nature 410 2001 974-979
48. C.A. Patel M. Mukhtar and R.J. Pomerantz Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells J. Virol. 74 2000 9717-9726
49. K. Muthumani et al. HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro Int. Immunol. 17 2005 103-116
50. R.G. Bryan et al. Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells Mol. Cell. Biol. 14 1994 7933-7942